LON:EVG - Evgen Pharma Stock Price, News & Analysis

GBX 16.62
0.00 (0.00 %)
(As of 08/18/2019 04:00 PM ET)
Today's Range
Now: GBX 16.63
50-Day Range
MA: GBX 17.53
52-Week Range
Now: GBX 16.63
Volume8,883 shs
Average Volume207,445 shs
Market Capitalization£22.05 million
P/E RatioN/A
Dividend YieldN/A
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesN/A
Cash FlowGBX 2.11 per share
Book ValueGBX 2.10 per share



Market Cap£22.05 million
Next Earnings DateN/A
OptionableNot Optionable

Receive EVG News and Ratings via Email

Sign-up to receive the latest news and ratings for EVG and its competitors with MarketBeat's FREE daily newsletter.

Evgen Pharma (LON:EVG) Frequently Asked Questions

What is Evgen Pharma's stock symbol?

Evgen Pharma trades on the London Stock Exchange (LON) under the ticker symbol "EVG."

What price target have analysts set for EVG?

1 brokerages have issued 1 year price objectives for Evgen Pharma's shares. Their predictions range from GBX 35 to GBX 113. On average, they anticipate Evgen Pharma's share price to reach GBX 74 in the next twelve months. This suggests a possible upside of 345.1% from the stock's current price. View Analyst Price Targets for Evgen Pharma.

What is the consensus analysts' recommendation for Evgen Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evgen Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evgen Pharma.

Has Evgen Pharma been receiving favorable news coverage?

Headlines about EVG stock have been trending negative this week, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evgen Pharma earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Evgen Pharma.

Who are some of Evgen Pharma's key competitors?

What other stocks do shareholders of Evgen Pharma own?

Who are Evgen Pharma's key executives?

Evgen Pharma's management team includes the folowing people:
  • Dr. Stephen J. Franklin, CEO & Exec. Director
  • Mr. Richard Anthony Moulson, CFO & Exec. Director (Age 57)
  • Ms. Liz Jenkins, Regulatory Consultant
  • Dr. Thomas Morris, Consultant & Medical Advisor of Oncology
  • Prof. Albena Dinkova-Kostova, Independent Scientific Advisor

How do I buy shares of Evgen Pharma?

Shares of EVG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Evgen Pharma's stock price today?

One share of EVG stock can currently be purchased for approximately GBX 16.63.

How big of a company is Evgen Pharma?

Evgen Pharma has a market capitalization of £22.05 million. Evgen Pharma employs 11 workers across the globe.View Additional Information About Evgen Pharma.

What is Evgen Pharma's official website?

The official website for Evgen Pharma is http://evgen.com/.

How can I contact Evgen Pharma?

Evgen Pharma's mailing address is The Colony 146 Brownlow Hill, Altrincham Road, WILMSLOW, SK9 4LY, United Kingdom. The company can be reached via phone at +44-151-7053532.

MarketBeat Community Rating for Evgen Pharma (LON EVG)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  291
MarketBeat's community ratings are surveys of what our community members think about Evgen Pharma and other stocks. Vote "Outperform" if you believe EVG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel